Du är här

2016-02-25

LivaNova plc: LivaNova PLC to Participate in Upcoming Investor Conferences

LONDON, Feb. 25, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN)
(LSE:LIVN) ("LivaNova" or "the Company"), today announced that the Company
will participate in the following conferences:

Vivid Sehgal, LivaNova's Chief Financial Officer, will present at the Cowen
and Company 36th Annual Health Care Conference in Boston on Wednesday, March
9, 2016 at 11:20 am Eastern Time.

André-Michel Ballester, LivaNova's Chief Executive Officer, will present at
the Barclays Global Healthcare Conference in Miami on Wednesday, March 16,
2016 at 8:30 am Eastern Time.

A live audio webcast of both sessions will be available by clicking on the
Investor Relations link on the LivaNova home page at www.livanova.com.

About LivaNova

LivaNova, headquartered in London, UK, is a global medical technology company
formed by the merger of Sorin S.p.A. ("Sorin"), a leader in the treatment of
cardiovascular diseases, and Cyberonics, a medical device company with core
expertise in neuromodulation. LivaNova transforms medical innovation into
meaningful solutions for the benefit of patients, healthcare professionals,
and healthcare systems. The Company employs approximately 4,500 employees
worldwide. With a presence in more than 100 countries, LivaNova operates as
three business units: Cardiac Rhythm Management, Cardiac Surgery, and
Neuromodulation, with operating headquarters in Clamart (France), Mirandola
(Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and has been admitted to the standard listing
segment of the Official List of the UK's Financial Conduct Authority and to
trading on the London Stock Exchange (LSE) under the ticker symbol "LIVN".

Safe harbor statement

This press release contains forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended and
Section 21E of the United States Securities Exchange Act of 1934, as amended.
Forward-looking statements are not historical facts but are based on certain
assumptions of management and describe the Company's future plans, strategies
and expectations. Forward-looking statements can generally be identified by
the use of forward-looking terminology, including, but not limited to, "may,"
"could," "seek," "guidance," "predict," "potential," "likely," "believe,"
"will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or
variations of these terms and similar expressions, or the negative of these
terms or similar expressions. Forward-looking statements contained in this
press release are based on information presently available to LivaNova and
assumptions that the Company believes to be reasonable, but are inherently
uncertain. As a result, our actual results, performance or achievements may
differ materially from those expressed or implied by these forward-looking
statements, which are not guarantees of future performance and involve known
and unknown risks, uncertainties and other factors that are, in some cases,
beyond the Company's control. Investors are cautioned that all such
statements involve risks and uncertainties, including without limitation,
statements concerning developing novel opportunities in heart failure, sleep
apnea and percutaneous mitral valve, creating new innovative solutions that
benefit patients, healthcare professionals, and healthcare systems, and
building significant shareholder value. Important factors that may cause
actual results to differ include, but are not limited to: (i) risks that the
businesses of Cyberonics and Sorin (together, the "combined companies") will
not be integrated successfully or that the combined companies will not
realize estimated cost savings, value of certain tax assets, synergies and
growth, or that such benefits may take longer to realize than expected; (ii)
the inability of LivaNova to meet expectations regarding the timing,
completion and accounting of tax treatments; (iii) risks relating to
unanticipated costs of integration, including operating costs, customer loss
or business disruption being greater than expected; (iv) our organizational
and governance structure; (v) reductions in customer spending, a slowdown in
customer payments and changes in customer demand for products and services;
(vi) unanticipated changes relating to competitive factors in the industries
in which LivaNovaoperates; (vii) the ability to hire and retain key
personnel; (viii) the ability to attract new customers and retain existing
customers in the manner anticipated; (ix) the reliance on and integration of
information technology systems; (x) changes in legislation or governmental
regulations affecting LivaNova; (xi) international, national or local
economic, social or political conditions that could adversely affect
LivaNova, its partners or its customers; (xii) conditions in the credit
markets; (xiii) business and other financial risks inherent to the industries
in which LivaNova operates; (xiv) risks associated with assumptions made in
connection with critical accounting estimates and legal proceedings; (xv)
LivaNova's international operations, which are subject to the risks of
currency fluctuations and foreign exchange controls; (xvi) and the potential
of international unrest, economic downturn or effects of currencies, tax
assessments, tax adjustments, anticipated tax rates, raw material costs or
availability, benefit or retirement plan costs, or other regulatory
compliance costs. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks and
uncertainties that affect the parties' businesses, including those described
in the "Risk Factors" section of the Registration Statement on Form S-4,
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K and other documents filed from time to time with the United
States Securities and Exchange Commission by LivaNova. LivaNova does not give
any assurance (1) that LivaNova will achieve its expectations, or (2)
concerning any result or the timing thereof, in each case, with respect to
any regulatory action, administrative proceedings, government investigations,
litigation, warning letters, consent decree, cost reductions, business
strategies, earnings or revenue trends or future financial results.

All information in this press release is as of the date of its release. The
Company does not undertake or assume any obligation to update publicly any of
the forward-looking statements in this press release to reflect actual
results, new information or future events, changes in assumptions or changes
in other factors affecting forward-looking statements, except to the extent
required by applicable law. If we update one or more forward-looking
statements, no inference should be drawn that we will make additional updates
with respect to those or other forward-looking statements. We caution you
not to place undue reliance on any forward-looking statements, which are made
only as of the date of this press release.

For more information, please visit www.livanova.com, or contact:
Investor Relations:

Vivid Sehgal
Chief Financial Officer
e-mail: investor.relations@livanova.com

Investor Relations and Media:
Greg Browne
Senior Vice President, Finance
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LivaNova plc via Globenewswire

HUG#1989197

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.